Coherus and Mark Cuban team up to offer discounted biosimilar Humira
TL;DR Summary
Coherus BioSciences plans to sell a biosimilar version of Humira at an 85% discount from AbbVie's price, and will work with Mark Cuban's generic drug company to make the medicine available directly to consumers for even less. The move has the potential to alter one of the most closely watched product rollouts by pharmaceutical companies in many years, as AbbVie is expected to face at least eight biosimilar rivals to Humira by the end of the year.
- Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts STAT
- Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients GlobeNewswire
- Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine STAT
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
65%
217 → 77 words
Want the full story? Read the original article
Read on STAT